Health Condition 1: null- Inflammatory ocular conditions where bacterial infection or a risk of bacterial ocular infection exists Health Condition 2: H018- Other specified inflammations of eyelid
Conditions
Interventions
Intervention1: Gatifloxacin 0.3 % + Difluprednate 0.05 % Eye Drops: Instill 1 drop four times a day for 7 days
Control Intervention1: Gatifloxacin 0.3% + Dexamathasone 0.1% eye drops: Instill 1 drop
Sponsors
Ajanta Pharma Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with inflammatory ocular conditions where bacterial infection or a risk of bacterial ocular infection exists. 2.Patients showing an anterior chamber cell score of not less than 2 at a day after surgery. 3.Written informed consent to participate to the trial.
Exclusion criteria
Exclusion criteria: 1.Patients < 18 & > 60 years. 2.Patients who took systemic administration of corticosteroids or immunosuppressive agents in the eyes before instillation of the investigational drugs; (patients who used aqueous preparations within 1 week or patient who used depot preparations within 2 weeks were excluded. 3.Patients who took systemic administration of non-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 3 days before instillation of the investigational drugs; 4.Patients who instilled of corticosteroids, no-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 24 hours before the pre-instillation observation (a day after surgery); 5.Patients who underwent perioperative and/or postoperative intravitreous injection of corticosteroids; 6.Patients who underwent sub-conjunctival injection 7.Patients who have intraocular hemorrhage with a degree that may affect the postoperative evaluations; 8.Patients who underwent gas tamponade at the surgery; 9.Patients with endogenous uveitis; 10.Patients having corneal epithelial detachment or corneal ulcer in the target eye; 11.Patients who are suspected of having viral, bacterial or mycotic keratoconjunctival disorders in the target or opposite eye; 12.Patients with glaucoma or ocular hypertension, or those with past history of IOP increased due to instillation of corticosteroids, or those whose IOP has been controlled by use of ophthalmic antihypertensive agents; 13.Patients showing IOP not less than 25 mmHg a day after surgery; 14.Patients who have allergy to corticosteroid drugs; 15.Patients who are required to wear contact lens during the study period; 16.Patients who are scheduled to undergo surgery of the opposite eye during the study period; 17.Patients who are pregnant or may be pregnant or lactating; 18.Patients who have participated in other clinical studies within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Slit Lamp Biomicroscopic ExaminationTimepoint: Day 0, Day 3, Day 5 and Day 7. | — |
Secondary
| Measure | Time frame |
|---|---|
| Conjunctival hyperaemia, Corneal and lid oedema, Ocular Infection, pain, photophobia and tearing will be assessed and observation will be graded as 0 Nil, 1 Mild, 2 Moderate, 3 Severe.Timepoint: Day 0, Day3, Day 5 and Day 7. | — |
Countries
India
Contacts
Public ContactDr Shailesh Singh
Ajanta Pharma Ltd, Advent
Outcome results
None listed